Annals of Surgical Oncology Sign the Guestbook
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Brower, S. T.
Right arrow Articles by Bleiweiss, I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brower, S. T.
Right arrow Articles by Bleiweiss, I.

Annals of Surgical Oncology, Vol 2, Issue 5 416-423, Copyright © 1995 by Society of Surgical Oncology

ARTICLES

Proliferative indices and oncoprotein expression in benign and malignant breast biopsies

S. T. Brower, P. I. Tartter, S. Ahmed, C. M. Brusco, K. Bossolt, C. Hayden and I. Bleiweiss
Department of Surgery, Mount Sinai Medical Center, New York, New York 10029, USA.

BACKGROUND: Prognostic factors are used routinely in the management of breast cancer. However, their potential for identifying precursor malignant lesions has not been assessed. METHODS: We have examined 285 breast biopsy specimens (140 benign, 145 malignant) for DNA ploidy, S-phase fraction, Ki-67 nuclear antigen proliferative indices, and HER-2/neu and epidermal growth factor receptor oncoproteins. RESULTS: When proliferative indices were compared between the benign and malignant groups, differences were noted for DNA ploidy, S-phase fraction, and cell cycling index (p < 0.0005). When the benign nonproliferative specimens were compared with the atypical/proliferative benign specimens, proliferative indices failed to show any differences. When the specific subset of proliferative/atypical benign breast tissue was compared with the malignant specimens, DNA index, S-phase fraction, and cell cycling index showed significant differences. The mean for epidermal growth factor receptor was greater in the non-proliferative group but not statistically significant (p < 0.1). HER-2/neu oncoprotein failed to show any differences between the benign and malignant groups. Within the atypical benign group, Ki-67 correlated strongly with S-phase fraction and HER-2/neu (p < 0.01). CONCLUSIONS: We have demonstrated that proliferative indices can differentiate between benign and malignant breast tissues but not among specific subgroups. In addition, epidermal growth factor may differentiate between nonproliferative and proliferative/atypical benign biopsy results. Oncoprotein determination, ploidy, and DNA proliferative indices may be useful in defining malignant and benign breast disease but are not useful in distinguishing between benign and malignant breast disease with an increased likelihood for malignant transformation.


This article has been cited by other articles:


Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
H. B. Nichols, A. Trentham-Dietz, R. R. Love, J. M. Hampton, P. T. Hoang Anh, D. C. Allred, S. K. Mohsin, and P. A. Newcomb
Differences in Breast Cancer Risk Factors by Tumor Marker Subtypes among Premenopausal Vietnamese and Chinese Women
Cancer Epidemiol. Biomarkers Prev., January 1, 2005; 14(1): 41 - 47.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
W.-Y. Huang, B. Newman, R. C. Millikan, K. Conway, B. S. Hulka, M. J. Schell, and E. T. Liu
Risk of Breast Cancer According to the Status of HER-2/neu Oncogene Amplification
Cancer Epidemiol. Biomarkers Prev., January 1, 2000; 9(1): 65 - 71.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1995 by the Society of Surgical Oncology.